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Evolutionary and network analysis 
of virus sequences from infants 
infected with an Australian 
recombinant strain of human 
parechovirus type 3
Soren Alexandersen  1,2,3, Tiffanie M. Nelson  1,2, Jason Hodge1,3 & Julian Druce4
We present the near complete virus genome sequences with phylogenetic and network analyses 
of potential transmission networks of a total of 18 Australian cases of human parechovirus type 3 
(HPeV3) infection in infants in the period from 2012–2015. Overall the results support our previous 
finding that the Australian outbreak strain/lineage is a result of a major recombination event that 
took place between March 2012 and November 2013 followed by further virus evolution and possibly 
recombination. While the nonstructural coding region of unknown provenance appears to evolve 
significantly both at the nucleotide and amino acid level, the capsid encoding region derived from the 
Yamagata 2011 lineage of HPeV3 appears to be very stable, particularly at the amino acid level. The 
phylogenetic and network analyses performed support a temporal evolution from the first Australian 
recombinant virus sequence from November 2013 to March/April 2014, onto the 2015 outbreak. The 
2015 outbreak samples fall into two separate clusters with a possible common ancestor between March/
April 2014 and September 2015, with each cluster further evolving in the period from September to 
November/December 2015.
The picornaviruses are small, single-stranded positive sense RNA viruses causing disease in animals and humans 
and include the human parechoviruses (HPeV). Like other picornaviruses, HPeV evolve rapidly due to nucleo-
tide substitutions and recombination events, generating strains associated with changed infectivity, virulence or 
host range. The first detected outbreak of HPeV type 3 (HPeV3) in infants in Australia occurred in and around 
Sydney in New South Wales in late 2013, with subsequent infection in other parts of Australia in the first part of 
2014. A second outbreak occurred across Victoria and Southern Australia in the second half of 2015. As described 
previously1 this latter outbreak included the first HPeV3 cases in infants seen at University Hospital Geelong and 
was shown to be caused by a novel recombinant strain of HPeV type 31. We now extend our previous study to 
include the near complete virus genome sequences and the phylogenetic and transmission network analyses of 12 
of the Geelong 2015 cases and another 6 Australian cases from 2012–2015 for a total of 18 HPeV3 infant cases in 
Australia. Thus, our study provides valuable, near complete genome HPeV3 sequences and explores the potential 
value of phylogenetic and network analyses for better understanding HPeV3 transmission and evolution over 
time.
HPeV type 1 (HPeV1) and 2 were initially classified as echoviruses 22 and 23 in the genus Enterovirus, but 
reclassified in 1998/99 into their own genus based on nucleotide and biological features including a lack of host 
cell protein synthesis shut-off during replication2–6. The RNA genome of HPeV is approximately 7300-7400 nucle-
otides with 5′ and 3′ untranslated regions (UTR) at each end of a single long open reading frame (ORF)7–9. 
The single ORF encodes a polyprotein including the P1 structural/capsid and the P2 and P3 nonstructural 
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proteins. The capsid proteins of HPeV consist of only 3 proteins, VP0, VP3 and VP1, as VP0, in contrast to 
some other picornaviruses, is not proteolytically cleaved into VP4 and VP27, 10. Some of the HPeV types have an 
arginine-glycine-aspartic acid (RGD) motif near the carboxy-terminus of VP1, thought to be the receptor-binding 
site likely binding to host cell integrins11, 12. However, this RGD motif is not present in HPeV3, HPeV7-16, the 
related rodent/zoonotic virus Ljungan virus or in some strains within HPeV types normally encoding the RGD 
motif, for example for HPeV47, 13–16. Like other picornaviruses, recombination of HPeV often involves break-
points at the very end of VP1 and thus may remove or add the RGD motif, or alternatively occur downstream in 
the nonstructural coding region7, 17–21.
HPeV infections are prevalent in humans and most often cause only asymptomatic/subclinical or mild gastro-
intestinal and/or respiratory disease. More severe disease including central nervous system (CNS) dysfunction 
may be seen in particular in infants and one relatively large study reported mortality among young infants as high 
as 6%22, 23. HPeV3 appears to cause more severe disease in young infants compared to the other HPeV types and 
is the most common type identified in cerebrospinal fluid (CSF) samples from young infants with CNS infection 
and/or sepsis-like presentation22. Evaluation by cranial magnetic resonance imaging (MRI) or ultrasound of a 
group of 10 infants with HPeV3 CNS infection showed abnormal periventricular white matter in all infants and 
for a number of the infants, clinical follow-up revealed sequelae including cerebral palsy, epilepsy, learning dis-
abilities, and visual impairment24, 25. Further cases like this including reports of autopsy cases of two infants that 
died with active HPeV3 infection and severe CNS disease are referenced in ref. 22. In regard to pathogenesis, it 
appears that HPeV3 may target vascular smooth muscle cells in the leptomeninges, and in the lung, and thus that 
clinical symptoms and severe CNS tissue damage may be caused by vascular changes22.
HPeV3 was first isolated in 1999 and reported in the literature in 2004 and subsequent surveillance suggests a 
two to three-year cycle between outbreaks11, 23, 26–33. The reason for this is not known and as these viruses are easily 
transmitted by the oral-faecal and respiratory routes30, it may be related to exposure and immunity within fam-
ilies e.g. outbreaks occurring when there is both an older sibling lacking prior HPeV3 exposure plus waning or 
no maternally derived HPeV3 passive immunity in the young infant30, 34. Studies from Japan have indicated that 
antibodies to HPeV3 are only present in 15% of children from 7 months to 1 year of age, but that seropositivity 
increases to 45% in 2–3 year old and to 85% in 4–6 year old children11, 35. Due to these factors, virus testing results 
and virus sequences available for analyses are likely to only represent a minority of HPeV3 infections. Therefore, 
transmission network analyses will help elucidate part of a much larger transmission network, i.e. will represent 
sequences sampled from severe disease in young infants among a much larger population of infected older chil-
dren and adults with mild or no clinical disease and thus not sampled and tested.
Molecular clock analyses have estimated that the parechoviruses have existed for approximately 400 years with 
HPeV3 and HPeV7 diverging approximately 150 years ago36. However, it appears that more recent strains have 
spread worldwide only within the last 20–30 years28, 37, and during this time, may have evolved into being more 
virulent. One such example may be the Yamagata 2011 lineage of HPeV3 shown to cause severe disease in young 
children and myalgia in adults38–40. We have previously shown that the first reported outbreaks of HPeV3 in 
infants in Australia in 2013/14 and 2015, respectively, were caused by a novel recombinant HPeV3 with the capsid 
encoding region closely related to the Yamagata 2011 lineage, while the nonstructural encoding region derived 
from an as yet unknown/unpublished HPeV(s)1.
We now present the near complete virus genome sequences with phylogenetic and network analyses of poten-
tial transmission from a total of 12 of the Geelong 2015 cases as well as from another 6 positive Australian cases. 
These include an early Australian sample from 2012 obtained by retrospective testing, samples from Sydney from 
2013 and 2015 in addition to two samples from Adelaide and one from Darwin from 2014 making a total of 18 
cases of HPeV3 in infants in Australia. Overall the results support our previous finding1 that the major recom-
bination event took place between March 2012 and November 2013 and we now show evidence of further tem-
poral virus evolution and possibly recombination. While the nonstructural coding region appears to be evolving 
both at the nucleotide and amino acid level, the capsid encoding region appears to be very stable, particularly 
at the amino acid level. This apparent stability of the virus capsid may indicate that development of a vaccine or 
antibody treatment to avoid severe disease in infants may be feasible. It should be noted that the ancestor of the 
nonstructural coding region of the Australian recombinant HPeV3 is still not known and further sequencing and 
publishing/depositing of results from cases worldwide should be a priority to further the understanding of gener-
ation, evolution, spread and possibly even host range of new/recombinant strains of HPeV3.
Results and Discussion
Next generation sequencing (NGS) was performed on RNA extracted from the clinical samples (Table 1) as 
well as on available virus isolates. The coverage and quality of the sequences obtained varied somewhat between 
samples and those with a lower coverage or quality were included in multiple runs. A total of 5 NGS runs were 
performed to obtain sufficient data to assemble high quality consensus sequences for all samples included. Sample 
coverage varied from approximately 83000 mapped reads with an average coverage of 2400 for sample CS-HP-
16018 (which is a sample from 2012 and not the novel recombinant Australian outbreak virus1, thus not fully 
covered by our Ampliseq panels), to 2.3 million mapped reads with an average coverage of 67000 for sample 
CS-HP-16012. Apart from samples CS-HP-16018 mentioned above and CS-HP-16003 for which we only had 
very limited sample material left from our previous study, samples averaged 0.5–1.5 million reads and an aver-
age coverage of 14000–50000. This allowed us to assemble high quality near complete virus genome consensus 
sequences from each sample apart from sample CS-HP-16018, where high quality sequences were obtained for 
the first approximately 5000 nucleotides only. For that sequence we have chosen to only report and include in our 
analyses the capsid encoding region from nucleotide 701–3013. All sequences generated have been deposited in 
GenBank under accession numbers KY556659-KY556676.
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We first compared sequences obtained from different sample types from the same patient (CSF and fae-
cal samples obtained from CS-HP-16004 and CSF, faecal and nasal samples from CS-HP-16006; Table 1). The 
sequences obtained from the different samples collected from the individual patient were in 100% agreement. 
These results support the robustness and accuracy of the NGS sequences and moreover, allowed us to focus on 
a single sequence from each case in the phylogenetic analyses. As a second step, we compared the sequences 
obtained from virus isolates (see Materials and Methods) to the sequences obtained from the corresponding 
clinical sample. For 4 out of the 6 virus isolates available, the obtained sequence of 7334 nucleotides were in 100% 
agreement with that obtained from the clinical sample, while sample CS-HP-16018 and CS-HP-16019 each had 
a single non-coding change between the clinical sample and the corresponding virus isolate. For sample CS-HP-
16018 the single non-coding nucleotide change was located in the capsid coding region and for CS-HP-16019 it 
was located in the 5′-UTR. The comparison between clinical samples and corresponding virus isolates served two 
purposes. First, it further supports the very high accuracy of the NGS generated sequences indicated by compar-
ing different sample types mentioned above. Second, it suggests that the obtained virus isolates do not appear to 
have been selected/adapted during the cell culture process and may accurately reflect in vivo virus, which is useful 
information to have if a virus isolate is used for animal trials or in vitro studies.
As a first step in our analyses of the sequences obtained, we screened for recombinants among the sequenced 
viruses using GARD (genetic algorithm recombination detection) analysis. We discovered in our previous study 
that the Australian HPeV3 outbreak virus is a recombinant, with the sequence up to approximately nucleotide 
3115 derived from a Yamagata 2011-like virus, whereas the downstream sequence is derived from recombina-
tion(s) with an as yet unknown/unpublished HPeV/s1. The analysis done here did not include CS-HP-16018 as we 
did not have the near full-length sequence and moreover, have already demonstrated that the virus in this sample 
is not the novel recombinant virus as in the other Australian HPeV3 samples sequenced, but rather consistent/
similar to a full, i.e. not further recombined, Yamagata 2011 lineage virus1. Interestingly, although only indirectly 
related to our analyses presented here and to our knowledge not reported in the literature, the Yamagata 2011 
lineage viruses reported38–40 and deposited in GenBank contain what appear to be two different clusters most 
likely derived by recombination at approximately nucleotide 5000 (equivalent to nucleotide 4300 in the deposited 
Yamagata 2011 lineage viruses as they only included the coding regions). These two clusters are represented by 
GenBank Accession number AB759207 in one of the two clusters and AB759204 and AB759205 in another. We 
inadvertently based our initial NGS panel on AB7592071 and this particular panel coincidentally resulted in high 
quality sequence for sample CS-HP-16018 up to approximately nucleotide 5000, consistent with this sample, from 
March 2012, being of full Yamagata 2011 lineage, but really matched most closely to the AB759204/AB759205 
GCEID 
identificationa
Age in 
weeksb
Sample 
typec
Short sample 
designationd Timee Home locationf
CS-HP-16001 <1 CSF CSF01 November 2015 20 km south east of Geelong
CS-HP-16003 7 CSF CSF03 December 2015 20 km south east of Geelong
CS-HP-16004 12 CSF CSF04 September 2015 20 km east of Geelong
Faecal FEC04
CS-HP-16005 8 CSF CSF05 October 2015 South Geelong
CS-HP-16006 4 CSF CSF06 October 2015 5 km south of Geelong
Faecal FEC06
Nasal NAS06
CS-HP-16007 11 CSF CSF07 October 2015 5 km east of Geelong
CS-HP-16008 3 CSF CSF08 September 2015 Central Geelong
CS-HP-16010 9 Faecal FEC10 September 2015 South Geelong
CS-HP-16012 4 Faecal FEC12 September 2015 South Geelong
CS-HP-16014 15 Nasal NAS14 October 2015 20 km north east of Geelong
CS-HP-16016 11 Nasal NAS16 November 2015 350 km north east of Geelong
CS-HP-16017 11 Faecal FEC17 September 2015 Central Geelong
CS-HP-16018 6 Nasal NAS18 March 2012 20 km east of Geelong
CS-HP-16019 1 CSF CSF19 November 2013 Sydneyg
CS-HP-16020 7 Faecal FEC20 September 2015 100 km north of Sydneyg
CS-HP-16021 7 Faecal FEC21 March 2014 Adelaideh
CS-HP-16022 19 Faecal FEC22 April 2014 Darwini
CS-HP-16023 11 Faecal FEC23 April 2014 Adelaideh
Table 1. Sample and patient information. The Table displays GCEID sample identificationa, age of the affected 
infant when samples takenb, the sample type including cerebrospinal fluid (CSF)c, short sample designationd, 
time of sample takene, and approximate home location of infantf. gSydney is located approximately 800 km 
north east of Geelong. hAdelaide is located approximately 630 km north west of Geelong. iDarwin is located 
approximately 3100 km north of Geelong. Each of the shown cases tested positive for HPeV by reverse-
transcription real-time polymerase chain reaction (rRT-PCR), conducted at the Victorian Infectious Disease 
Reference Laboratory (VIDRL). The Table only includes data for samples for which we had sufficient sample 
material to produce high quality near full-length HPeV3 sequences.
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cluster/recombinant and not the AB759207 cluster/recombinant. Nevertheless, based on BLAST comparison to 
all sequences available in the NCBI databases, the Yamagata 2011 lineage(s) of viruses are the closest related to 
our Australian HPeV3 outbreak viruses in the region up to approximately nucleotide 3100 (the capsid encoding 
region) and consequently are included in our initial phylogenetic analysis. In any event, GARD analysis of the 
full sequence and the coding region from nucleotide 701 to 7231 of our Australian HPeV3 virus sequences, 
(excluding CS-HP-16018 as mentioned above), indicated possible sites of recombination at nucleotide 997 and 
nucleotide 3025 or 3550. The level of significance only reached p = 0.01–0.05 and likely reflects the impact of 
slight differences in evolutionary rates among the regions derived from previous recombination event(s)1. The 
sequences found to have differences in topologies of segments in the GARD analysis were samples CS-HP-16003, 
16006, 16007, 16010, 16014, 16017 and 16020, the potential importance of this is addressed later in the discus-
sion. Nevertheless, in our phylogenetic analyses described below, we looked at the regions both separately and 
as full-length sequences to see an effect, if any, of a prior site of recombination. Sequences were divided into the 
capsid encoding region (nucleotides 701–3013); the nonstructural proteins encoding region (nucleotides 3014–
7231); the full protein encoding region/ORF (nucleotides 701–7231); or finally, the full-length sequences from 
nucleotide 1–7334. The dataset from nucleotides 701–3013 included either the 17 sequences from the Australian 
samples containing the novel recombinant strain or another set with 21 sequences containing these 17 Australian 
recombinant virus samples and in addition sample CS-HP-16018, an Australian sample from 2012 with a fully 
Yamagata 2011 lineage virus, as well as the 3 closest related Yamagata 2011 virus sequences obtained from NCBI 
(i.e. AB759204, AB759205 and AB759207). For the remaining datasets we only included the 17 Australian sam-
ples containing the novel recombinant HPeV3, as the region downstream of the capsid coding region is likely to 
be derived from a previous recombination event/s and consequently will have a different evolutionary history 
than the fully Yamagata 2011 lineage viruses1.
The transition/transversion bias, nonsynonymous (dN)/synonymous (dS) nucleotide substitutions per site 
ratio (dN/dS), indication of positive or negative selection of sites and number of variable nucleotide and amino 
acid sites in the datasets are shown in Table 2. The range of the calculated transition/transversion bias in the 
datasets was from 7.85–9.68 using the maximum likelihood (ML) method and from 9.1–18.2 using the maxi-
mum composite likelihood (MCL) method depending on the dataset. This shows that the variation among the 
sequences is heavily biased towards transitions, in particular in the capsid encoding region that also had the 
lowest dN/dS ratio of 0.06 compared to the nonstructural coding region and the full ORF with a ratio of 0.16 and 
0.13, respectively. This is consistent with a strong indication of negative/purifying selection in the capsid coding 
region and some indication of positive selection at a few sites in the nonstructural coding region (Table 2). The 
sites of potentially positive selection included codon 826 in the 2 A coding region where samples from 2013 and 
2014 had a lysine (CS-HP-16019, 16022, 16023) or an arginine (CS-HP-16021), while the Sydney sample from 
2015 (CS-HP-16020) had a methionine and all 12 Geelong 2015 samples had an isoleucine. The other two poten-
tially positive selected codons were codon 1502 in the 3 C coding region having a serine in most of the samples, 
but a glycine in samples CS-HP-16003, 16006, 16007 and 16014 and finally codon 2067 in the 3D coding region 
having an alanine in most samples, but a valine in samples CS-HP-16001, 16003, 16006, 16007, 16014 and 16017. 
The significance of these changes, if any, is currently unknown.
The next step was to do phylogenetic inference of the sequence datasets by Maximum Likelihood (ML) phy-
logenetic analyses using the MEGA 6 software. Phylogenetic trees are shown in Figs 1–3.
Overall the ML phylogenetic analyses show that the capsid region of the Australian recombinant HPeV3 virus 
sequences are related to each other and more distantly to the Yamagata 2011 virus sequences. The Australian 
virus sequence from 2012 (sample NAS18/CS-HP-16018) has the closest relation to the Yamagata 2011 virus 
while the other Australian virus sequences from 2013/14 are more related to the Yamagata 2011 sequences than 
Sample set GARD
SLAC 
p0.05
FEL 
p0.01 FEL p0.05
IFEL 
p0.05 REL 100 dN/dS
Tra/
Trv-ML
Tra/Trv-
MCL NT diffs NT% AA diffs AA%
701-3013 incl 
sample18 & Yamagata nil nil
neg cod 
713
neg 7 
codons
neg cod 
713 neg 55 codons 0.061 9.17 9.11 64/2313 2.77 9/771 1.17
701-3013 17 samples nil nil nil
neg codon 
53, 175 & 
511
nil neg 25 codons 0.060 9.68 18.2 29/2313 1.25 4/771 0.52
3014-7234 A 17 
samples nil nil nil nil nil
POS codon 
55, 731&1296 
REM add 771 to 
codon
0.160 8.33 9.69 117/4218 2.77 28/1406 1.99
701-7234 A 17 samples nt 3550 p0.01
neg 
codon 53 
& 175
neg 
codon 53 
& 175
neg codon 
53, 175 & 
511
neg 
codon 53 
& 175
POS codon 826, 
1502 & 2067 0.132 8.7 10.62 146/6531 2.24 32/2177 1.47
1-7334 A 17 samples
nt 997 p0.01 
& nt 3025 
p0.05
NA NA NA NA NA NA 7.85 9.52 154/7334 2.1 NA NA
5′-UTR 1-700 ND NA NA NA NA NA NA 8.01 2.84 8/700 1.14 NA NA
3′UTR 7232-7334 ND NA NA NA NA NA NA NA NA 0/103 0 NA NA
Table 2. Information about the sequence datasets analysed. The sample sets and results of various types of 
analyses are shown; see Materials and Methods and Results and Discussion sections for details. Tra/Trv is the 
transition/transversion bias. Nucleotide (NT) and amino acid (AA) sites with differences within each dataset 
are also shown.
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the Australian virus sequences from 2015. This latter group partitioned into two clusters; cluster 1 with CSF 
samples CS-HP-16003, 16004, 16005, 16006, 16007, faecal samples CS-HP-16010, 16017, 16020 and nasal sample 
CS-HP-16014 and a cluster 2 with CSF samples CS-HP-16001, 16008, faecal sample CS-HP-16012 and nasal 
sample CS-HP-16016 falling separately (Fig. 1A and B). It should be noted that this clustering may have been 
caused by another recombination event as the samples in cluster 1, with the exception of CS-HP-16004 and 16005, 
all were identified by the GARD analysis as having potential recombination sites or other cause of incongruent 
evolution as compared to the other samples included here. Interestingly, the analysis indicated that the Australian 
2013/14/15 recombinant outbreak strain/lineage was more closely related to AB759204 Yamagata 2011 than to 
the “non-recombinant” 2012 Australian virus (nasal sample CS-HP-16018). The midpoint rooted tree obtained 
for the 17 Australian recombinant virus sequences for the capsid region (Fig. 2A) is very similar to that for the 
nonstructural coding region (Fig. 2B) although the variability for the nonstructural coding region is somewhat 
higher (Fig. 2 and Table 2). A similar picture and relationship is also evident in the trees for the full ORF (Fig. 3A) 
and for the full sequence from nucleotide 1–7334 (Fig. 3B). Thus, although the different regions appeared to be 
under different evolutionary pressures, inferences as shown by the clustering and topology of the trees gener-
ated, were relatively robust. Overall, this analysis indicated that the 17 Australian recombinant outbreak virus 
Figure 1. Maximum Likelihood (ML) phylogenetic tree based on the capsid encoding region from nucleotide 
701–3013 of the 18 Australian HPeV3 sequences together with the closest related Yamagata 2011 virus 
sequences. Sequences were aligned using Clustal W and phylogenetic analysis was conducted using MEGA 
6 and the Maximum Likelihood (ML) method based on the Tamura-Nei model51. The tree with the highest 
log likelihood is shown. Bootstrap test involved 1000 replicates to determine reliability of the inferred tree. 
The numbers at nodes represent bootstrap values. Branch lengths are scaled according to the numbers of 
nucleotide substitutions per site. Details of the samples are given in Table 1 and in the text. Samples 759204, 
759205 and 759207 are the closest related Yamagata 2011 lineage virus sequences and taken from NCBI with the 
corresponding accession numbers: AB759204, AB759205, AB759207. Based on information from AB759206 
(HPeV3 Yamagata 2011 lineage39), the structural/capsid coding region is from nucleotide 701–3013 and the 
nonstructural protein coding region from 3014–7231 and inferred from that the 5′-UTR spans nucleotide 1-700 
and the 3′-UTR from 7232–7334 including 12 As of the poly-A tail. A) Midpoint rooted tree and B) rooted on 
the closest related non-Australian sequence, AB759204.
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sequences had the 2013/14 virus sequences clustering together while the 2015 virus sequences fell into two sepa-
rate discrete clusters as mentioned above.
Phylogenetic transmission network construction was then done using the program Network v5. It should 
be emphasized that our virus sequences all came from severely ill infants and likely only represent a fraction of 
infected individuals. Consequently, the aim was not to look at direct transmission between these cases, but rather 
to look for an indication of a potential transmission network likely containing a large number of unsampled 
infections among older children and adults (likely to only show mild or no clinical symptoms and therefore not 
tested for HPeV). Similar to the ML phylogenetic analysis shown above, we did this for the individual regions, 
for the full ORF and for the full sequence. Similar to what is mentioned above, we found the potential transmis-
sion networks generated to be very similar and again suggesting that the closest ancestor for the capsid region 
of the recombinant Australian 2013/14/15 virus sequences was AB759204 of the Yamagata 2011 virus lineage. 
Interestingly, while the Australian 2012 “non-recombinant” virus sequence (sample NAS18/CS-HP-16018) clearly 
was closely related to the Yamagata 2011 virus sequences, it may not be the direct ancestor of the subsequent 
Australian outbreaks that may be caused by separate introduction(s) (Fig. 4A) [21 sequences, capsid only]. As the 
apparent transmission networks for the regions, the full ORF and the full sequence were very similar, and more-
over the non-coding regions only had a total of 8 variable sites (Table 2) we have chosen to just show the network 
inferred from the full ORF consisting of 6531 nucleotides and 2177 codons (Fig. 4B) [17 sequences]. The potential 
transmission network shown in Fig. 4B corresponds well to the ML tree in Fig. 3A. Furthermore, it also supports 
the temporal evolution from the first Australian recombinant virus sequence from November 2013 to March/
April 2014 onto the 2015 outbreak. Also evident are the two 2015 clusters mentioned previously with a likely 
common ancestor between March/April 2014 and September 2015 and each cluster further evolving in the period 
from September to November/December 2015. The only discrepancy in this apparent temporal network is faecal 
sample FEC17 (CS-HP-16017) that is positioned after samples from October yet was taken in September 2015. 
Figure 3. Maximum Likelihood (ML) phylogenetic trees based on the either the full open reading frame 
from nucleotide 701–7231 or the full length sequence from nucleotide 1–7334 of the 17 Australian 2013–2015 
HPeV3 sequences. Sequences were aligned using Clustal W and phylogenetic analysis was conducted using 
MEGA version 6 and the Maximum Likelihood (ML) method. The tree with the highest log likelihood is shown. 
Bootstrap test involved 1000 replicates to determine reliability of the inferred tree. The numbers at nodes 
represent bootstrap values. Branch lengths are scaled according to the numbers of nucleotide substitutions per 
site. (A) Midpoint rooted tree based on the full open reading frame from nucleotide 701–7231. (B) Midpoint 
rooted tree based on the full length sequence from nucleotide 1–7334.
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However, as HPeV is very stable in the environment, we anticipate that this infection would include many unsam-
pled infected individuals. In this outbreak, this discrepancy could most likely be explained by case CS-HP-16017 
being infected relatively early in September 2015, possibly by someone at the end of a long unsampled network, 
or alternatively, may be explained by some cases in that cluster (i.e. CSF samples CS-HP-16006 and CS-HP-16007, 
both sampled in October) derived from cases that have been infected from virus excreted into the environment 
already in September. Another difference between the ML tree in Fig. 3A and the transmission network in Fig. 4B 
involves sample CSF19 (CS-HP-16019) which although sampled in November 2013 is not consistently basal to the 
Australian samples from early 2014 (FEC21, 22 and 23). The reason for this is unknown, but may at least in part 
be explained by the fact that CSF19 appears to be more closely related to sample FEC23 than to the other samples 
from 2014 and moreover, that the trees get somewhat skewed by the fact that FEC22 is more closely related to 
the included Yamagata 2011 lineage viruses than to CSF19. However, considering that these particular samples 
(CSF19 and FEC21, 22 and 23) represent a very few samples from affected infants separated by many hundreds 
of kilometres (Table 1), speculation on exact causes is not possible apart from noting the fact that although both 
collected from cases in Adelaide and only separated in time by one month, samples FEC21 and FEC23 appear to 
represent two slightly different clusters somewhat similar to what is observed for the Geelong 2015 cases (Fig. 4A 
and B).
In addition to the temporal aspect, we also attempted to look at the apparent transmission network from a 
spatial perspective using the approximate home location of each case (Table 2). Not unexpectedly, considering 
the anticipated large number of unsampled infected individuals and the likely wide travel network involved, in 
particular in relation to the holiday season up to December, we could not detect any spatial connection between 
either the 2015 clusters, or the earlier Australian virus sequences. However, for the 2015 virus sequences it is 
interesting to note that those with the highest number of nucleotide differences and located most distant in the 
Figure 2. Maximum Likelihood (ML) phylogenetic trees based on either the capsid or nonstructural proteins 
encoding region of the 17 Australian 2013–2015 HPeV3 sequences. Sequences were aligned using Clustal W 
and phylogenetic analysis was conducted using MEGA version 6 and the Maximum Likelihood (ML) method. 
The tree with the highest log likelihood is shown. Bootstrap test involved 1000 replicates to determine reliability 
of the inferred tree. The numbers at nodes represent bootstrap values. Branch lengths are scaled according to 
the numbers of nucleotide substitutions per site. (A) Midpoint rooted tree based on the capsid encoding region 
from nucleotide 701–3013. (B) Midpoint rooted tree based on the nonstructural proteins encoding region from 
nucleotide 3014–7231.
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transmission networks are the faecal sample CS-HP-16020 taken in Sydney and the CSF CS-HP-16001, CS-HP-
16003, CS-HP-16008 and nasal CS-HP-16014, CS-HP-16016 samples taken from infants treated at University 
Hospital Geelong which, except for CSF sample CS-HP-16008, have home addresses located outside or even at 
some distance from Geelong (Table 1 and Fig. 4B).
We have here reported near complete virus genome sequences from 17 samples and a partial sequence of one 
sample essentially doubling the availability of near complete HPeV3 genome sequences in the NCBI databases. 
Furthermore, we show that consensus sequences obtained from different sample types or directly from clinical 
sample as compared to virus isolate are essentially identical. Overall our results support our previous finding that 
the major recombination event leading to the generation of the Australian 2013–2015 outbreak virus took place 
between March 2012 and November 2013 possibly followed by additional recombination events contributing to 
the evolution of seperate clusters. While the nonstructural coding region derived from an as yet unknown HPeV 
Figure 4. Median-joining phylogenetic network of the analysed HPeV3 sequences. The networks shown 
include all of the most parsimonious trees linking the sequences. Each unique sequence is represented by 
a circle showing the identity and frequency in the dataset. Branch length is proportional to the number of 
nucleotide differences and the number of nucleotide differences between nodes are shown in red. (A) Network 
based on the capsid encoding region from nucleotide 701–3013 and including all 18 Australian sequences as 
well as the 3 selected Yamagata 2011 lineage virus sequences as indicated in Fig. 1. The larger circle labeled 
CSF06 also includes samples NAS14 and FEC17 as the sequences of these 3 samples/cases were identical for 
the capsid encoding region. Year of samples obtained shown at the bottom. (B) Network analysis based on the 
full open reading frame from nucleotide 701–7231 and only including the 17 Australian virus sequences from 
2013–2015, i.e. the novel Australian recombinant HPeV3. Month and year of samples obtained shown at the 
bottom. For more details on samples see Table 1.
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appears to be evolving both at the nucleotide and amino acid level and may still be evolving/adapting to its full 
replicative potential in this recombinant virus setting, the capsid encoding region appears to be very stable, in 
particular at the amino acid level. As we have noted previously, the stability of the virus capsid indicates that 
development of a vaccine or antibody treatment to avoid severe disease in infants may be feasible. However, the 
ancestor of the nonstructural coding region of the Australian recombinant HPeV3 is still not known and we 
encourage further sequencing and publishing/depositing of results from cases worldwide in order to further the 
understanding of generation, evolution, spread and possibly even host range of such new/recombinant strains of 
HPeV3.
Materials and Methods
Clinical specimens and virus isolates. An outbreak of HPeV3 was identified in infants in the Geelong 
area of Victoria, Australia during August-December 2015 and a total of 16 cases were identified at the University 
Hospital Geelong as described previously1. For the studies described here we had available a total of 15 sam-
ples from 12 of these cases and also 3 stored clinical samples from the Victorian Infectious Disease Reference 
Laboratory (VIDRL) collection described previously1. An additional 3 positive samples selected from VIDRL’s 
stored collection of HPeV3 positive samples from Australia provided a total of 21 clinical samples from 18 cases 
of HPeV3 in infants in Australia; see Table 1 for details.
Virus isolates from the following 6 samples were also available for analysis: CS-HP-16006 faecal and nasal 
swab samples, CS-HP-16004 faecal sample, CS-HP-16018 nasal sample, CS-HP-16019 CSF sample and CS-HP-
16020 faecal sample. These virus samples were cultured on monolayers of Vero cells as described previously1.
All samples were stored at −80C and RNA extracted and converted into cDNA as described previously1.
The studies described here were performed in accordance with relevant guidelines and regulations and was 
provided with ethical exemption by the Barwon Health Human Research Ethics Committee.
Next generation sequencing (NGS) of HPeV-positive samples. As described previously1, we initially 
constructed a composite reference genome from related HPeV3 sequences available in NCBI (National Center 
for Biotechnology Information) and used this initial reference (here called composite reference 1, see ref. 1 to 
design a custom Ion AmpliSeq Panel (here referred to as panel 1) for use with Ion Torrent S5 System (Thermo 
Fisher Scientific, Vic. Australia). Based on initial NGS results and additional Sanger sequencing (described previ-
ously1), we subsequently updated this initial reference sequence (updated reference available as GenBank acces-
sion number KY020128) and used that to design an updated Ion Ampliseq Panel, referred to as panel 2. Based on 
additional NGS runs, we further updated the reference sequence and designed a third Ion Ampliseq Panel, here 
referred to as panel 3. Details of panel 2 and 3 can be seen online (Supplementary Table S1).
Extracted RNA converted to cDNA from all samples were PCR-amplified with the Ion AmpliSeq Library Kit 
2.0 and Ion AmpliSeq Panel 1, 2 or 3. The panels comprise 37 or 38 overlapping primer sets split into 2 pools 
per sample and amplified with the 5X Ion AmpliSeq HiFi Master Mix. The details of our NGS protocol has been 
described in detail previously1 and for the results described here we only made minor adjustments including 
raising the number of initial PCR cycles from 30 to 35 cycles and then leaving out the post-amplification step 
and finally, we used the Ion Library TaqMan™ Quantitation Kit to quantify the amplified libraries. Libraries were 
then pooled prior to loading onto Ion 530 Chips and loading into the Ion Chef Instrument. Following template 
preparation, the chips were run on the Ion Torrent S5 System following company protocols. NGS and associated 
reactions were performed at the Geelong Centre for Emerging Infectious Diseases (GCEID), Geelong, Victoria, 
Australia. For the NGS results described here we did a total of 5 Ion Torrent S5 runs with a total of 6 Ion 530 Chips 
generating a total of approximately 25 billion nucleotides.
Next generation sequence analyses. Sequences obtained from the Ion Torrent S5 were analysed based 
on each sample having a unique barcode. Raw sequences were analysed using the Ion Reporter Software con-
tained within the Ion S5 Instrument using either of the 3 reference genomes or various HPeV reference genomes 
from NCBI. Obtained reads were then visualised and analysed using the Integrative Genomics Viewer (IGV)41. 
IGV calculates the consensus sequence for the NGS results for each sample as described by Cavener42; if the 
frequency of a single nucleotide at a specific position is greater than 50% and greater than twice the number of 
the second most frequent nucleotide it is assigned as the consensus nucleotide or if the sum of the frequencies 
of two nucleotides is greater than 75% (but neither meet the criteria for a single nucleotide assignment) they are 
assigned as co-consensus nucleotides. If no single nucleotide or pair of nucleotides meets the criteria, IGV assign 
an ‘N’. In the few occasions where our consensus sequences contained co-consensus nucleotides at a given posi-
tion, we manually inspected the results and assigned a single nucleotide when a given nucleotide was present in 
60% or more of the reads. The final assembled virus genome sequences were based on the NGS results indicated 
above, but also included nucleotides 1–29 and 7292–7334 (the very 5′- and 3′end sequences). These did not derive 
directly from the NGS sequencing, but are assumed based on: (i) the high efficiency of the end-primers used; 
(ii) comparison to other closely related sequences, and (iii) the fact that the rest of the 5′- and 3′-UTR sequences 
obtained were highly conserved as indicated in the results.
Phylogenetic analyses and transmission network construction. Screening for recombinants among 
the sequenced viruses were done using GARD (genetic algorithm for recombination detection) analyses43, 44 and 
the HyPhy package45, 46 available on the Datamonkey webserver and using the HKY85 substitution model as sug-
gested by using the automatic Model Selection Tool available on the site. The GARD technique identifies evidence 
for recombination breakpoints by searching multiple sequence alignments for phylogenetic incongruences.
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To understand phylogenetic relationships among the HPeV3 sequences, they were compared to the NCBI 
database using nucleotide BLAST (Basic Local Alignment Search Tool)47, 48 and aligned using Clustal-W49. 
Maximum Likelihood phylogenetic analyses were conducted using the MEGA 6 software50 and the Tamura-Nei 
model51 (identical results were obtained using the HKY85 and the HKY + G models, data not shown). The robust-
ness of different nodes was assessed by bootstrap analysis using 1000 replicates. To understand the chains of 
transmission between obtained samples, sequences were used to construct phylogenetic (transmission) networks 
using the Median Joining method implemented in the program Network v5 (http//www.fluxus-engineering.com) 
developed to reconstruct all possible shortest, least complex phylogenetic trees (all maximum parsimony) and 
depict this as a network. The parameter epsilon was set at the same value as the weight of characters used to cal-
culate the genetic distances (weight value = 10) as described previously52. As the virus sequences available for this 
analysis most likely only represent a minority proportion of HPeV3 infections occurring in the total transmission 
network, i.e. only represent sequences sampled from severe disease in young infants among a much larger popu-
lation of infected older children and adults with mild or no clinical disease and thus not sampled, connections in 
the transmission network are not an indication of direct contact transmission between individual cases. Rather, it 
should be viewed as cases linked by chains of transmission that include an unknown number of mild or undiag-
nosed infections, yet still able to indicate temporal evolution and chains of transmission.
Analysis of selection pressure. Transition/transversion bias was estimated using Maximum Likelihood 
(ML) and Maximum Composite Likelihood (MCL) analysis available in MEGA 6. Site-specific selection pressures 
were measured as nonsynonymous (dN) -synonymous (dS) nucleotide substitutions per site and estimated using 
the single-likelihood ancestor counting (SLAC), fixed-effects likelihood (FEL), internal fixed-effects likelihood 
(IFEL), and random effects likelihood (REL) methods available at the Datamonkey online version of the HyPhy 
package. All analyses utilized the HKY85 nucleotide substitution model, which was tested as the best fitting 
model for the data sets, and employed input Neighbor Joining phylogenetic trees. A cut-off p-value to classify a 
site as positively or negatively selected was set at 0.01 or 0.05 for SLAC, FEL, and IFEL methods and the cut-off 
value for the Bayes factor in the REL method was set at 100 to reflect a positive or negative selection at a given site 
as described previously52.
Data Availability. All sequences generated have been deposited in GenBank under accession numbers 
KY556659-KY556676. Other datasets generated or analysed during the current study are available from the cor-
responding author on reasonable request.
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